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INTRODUCTION 
1. BACKGROUND AND LITERATURE REVIEW 
1.1. Background 
Deaths from non-communicable diseases (NCDs) accounted for two out of every three deaths in 
2010.1  Cardiovascular disease (CVD) has been the leading cause of death from 1990 to 2013.2 By 
2020, CVD will have become the leading cause of death and disability in the world, and the current 
geographic distribution of the burden caused by CVD is not expected to change.3 However, 80% of 
the burden of CVD is borne by low and middle-income countries where resources are scarce.4 
Cardiovascular disease is secondary to atherosclerosis that evolved over the years, and is the 
consequence of a complex interaction between many risk factors. Among major risk factors such as 
obesity, lipid disorders and tobacco use, hypertension (HT) is the leading condition responsible for 
deaths due to CVD worldwide.4 An efficient control of HT and other risk factors is one of the key 
answers to the CVD pandemic. This response starts with the identification of patients at high risk of 
developing cardiovascular events like stroke and ischaemic heart disease (IHD), since they 
represent those who benefit the most from pharmacologic interventions. This discriminative 
approach of selecting patients on the basis of their potential cardiovascular risk (CVR) is cost-
effective and relevant for primary care in low and middle-income countries.5.6 There are various 
scoring systems to achieve this cost-effectiveness, but it would be imperative to detect which of 
these systems are cost-efficient; therefore the need to carry out this study. 
1.2. Hypertension, cardiovascular risk factors and cardiovascular diseases 
A diagnosis of HT is made when the average of two or more diastolic BP measurements on at least 
two subsequent visits is ≥90 mm Hg, or when the average of multiple systolic BP readings on two or 
more subsequent visits is consistently ≥140 mm Hg.7 Hypertension is prevalent worldwide and 
studies are predicting a rise in NCDs in general, and HT in particular.4.8 An increased incidence and 
prevalence of HT and cardiovascular risk factors (CVRFs) should also be expected in South Africa.9 
Many factors can explain this anticipated trend, including epidemiological transition. Over the next 
three decades, various reports are predicting a rise in CVDs including HT.10 In a recent multicentre 
screening campaign including 47,443 adults in six middle-income countries, HT prevalence was 
found to vary between 23% and 83%; with up to 87% undiagnosed or untreated hypertensive 
patients at one site.11 An early population-based survey conducted in 1998 aiming to determine the 
prevalence of HT in South Africa found a 21% HT prevalence using the cut-off-point of 140/90 
mmHg.12 A more recent survey result has shown a slight increase in prevalence from 25% in 2003 
to 30% in 2013.13 There is a similar increasing trend in the prevalence of NCDs such as diabetes 
and HT in Sub-Saharan Africa.14 
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Arterial hypertension (HT) remains a major public health concern. Hypertension is asymptomatic for 
a long time before and after it has been diagnosed, giving patients a false sense of well-being. During 
that period end-organ damage takes place, leading to complications many years later. Uncontrolled 
HT leads to cardiovascular complications or events such as stroke, coronary artery disease and 
renal failure. All such complications or atherosclerotic CVDs are having a direct impact on 
productivity and quality of life. Many strategies to control HT have been studied and have shown 
efficacy.15.16 Challenges to reach an acceptable control of blood pressure (BP) vary according to 
local specificity. In high-income countries, challenges lie in individual aspects. In low and middle-
income countries, organisational and health systems encounter problems such as unavailability of 
tools involved in HT care like a calibrated BP machine, an efficient patient record system, the supply 
of medication and the level of care worker awareness of guidelines. This last aspect is illustrated by 
a study conducted in Cape Town, South Africa, where primary health care (PHC) practitioners’ 
knowledge of HT and their understanding of the South African national guidelines on HT have been 
found to be poor.17 
The high prevalence of HT in PHC in South Africa has been demonstrated by many recent studies. 
In a large multicentre prospective cross-sectional survey conducted on South African PHC including 
24,561 consultations, HT with cardiovascular symptoms appeared to be the leading reason for 
encounters, comprising 9,5% of reasons to consult a public primary care practice.18 Adejayan found 
similar results in an equivalent prospective cross sectional study conducted in the North West 
Province including 5,000 reasons for encounters and diagnoses recorded in primary care.19 The 
leading single cause of these encounters was related to HT, accounting for 16% of all diagnoses. 
Further results from the same survey have shown that the three leading diagnoses were HT (12.0%), 
upper respiratory tract infection (5.3%) and HIV/AIDS (3.9%).18 
1.3. Cardiovascular risk assessment 
The World Health Organization (WHO), the International Hypertension Society (IHS) as well as many 
other guidelines recommend the use of the absolute or global CVR approach rather than the 
individual risk approach when treating HT.20,21,22,23 The absolute CVR approach is cheaper and more 
cost-effective, and saves more lives as compared to the individual risk treatment approach.24 The 
global CVR approach is interchangeably referred to as the global risk assessment (GRA).25 The 
GRA aims to determine the global risk score (GRS) by adding, in a mathematical cardiovascular 
predictive equation, values of CVRF present in an individual.26 From this cardiovascular grading, a 
specific treatment modality will be initiated. The cardiovascular grading may be expressed either in 
cardiovascular level clustering such as low, moderate or high added CVR (South African guideline) 
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or in percentage (Framingham equation). 20,21 The treatment of individual risk factors was used in the 
past as opposed to the GRA, but the former is no longer supported as it has been demonstrated to 
be non-cost-effective and clinically irrelevant.27 With the single risk factor approach, some individuals 
presenting with isolated risk factors would be treated with unnecessary medication while others with 
many risk factors would receive only treatment for the recognised risk factors. There is currently a 
universal agreement to use the GRA, and this is reflected in different national guidelines.21, 28 
The most popular equation used in CVR assessment is derived from the Framingham cohort study, 
which was established in East Boston in the United States of America in 1948. To date, 5,209 adults 
between 30 and 62 years of age have been recruited, predominantly of white origin.29 The 
Framingham risk score derived from this study included non-laboratory-based risk factors such as 
smoking status as well as laboratory-based risk factors such as the LDL-cholesterol level. One of 
the advantages of a cardiovascular risk estimate (CVRE) is that it helps in predicting the likelihood 
of cardiovascular events such as stroke and IHD. A CVR equation such as this assists the clinician 
in deciding on the level and modality of preventive measures to be prescribed for an individual 
patient. For example, with the GRS recommended by the European Hypertension Society and the 
European Society of Cardiology (EHS-ESC), a patient assessed as having low added CVR will start 
a treatment consisting of lifestyle modification and BP monitoring for three to six months, whereas 
one who has high added CVR will be immediately started on medication in addition to lifestyle 
modification.30 In a given population, the prevalence of certain risk factors combined with 
environmental and genetic factors will dictate the occurrence of specific cardiovascular events. For 
example, in India and among Caucasians, IHD is more prevalent than stroke, while in the black 
population stroke is more predominant as compared to IHD.31 These geographic repartitions of 
cardiovascular events imply that the original population must only use a specific CVRE or at least 
have a validation study prior to its use. 
 
1.4. Laboratory and non-laboratory-based cardiovascular assessments 
Many CVR scores with specific advantages and limitations have been developed. The frequently 
quoted Framingham Risk Score derived from the study carrying the same name is frequently cited 
in medical literature. The Framingham study is the largest cohort study in the field of cardiovascular 
estimation with a long follow-up period.29 This study included various racial and ethnic groups with a 
dominance of Caucasian participants, and is regarded as a reference in CVRE.32 Unfortunately the 
score cannot be used universally because of risk factor prevalence variability and the influence of 
genetic and ethnic factors on the global CVR level. In Europe, many other scores have been 
developed, among them the NHAES score, the Q-RISK2-2011 and the Reynold score.33 They are 
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validated specifically for European populations. In Sub-Saharan Africa, the estimation of CVR is 
performed based on research developed elsewhere. The WHO recommends the use of the modified 
Framingham equation adapted for each region of the world.5,34 In South Africa, the guidelines 
developed by the South African Hypertension Society (SAHS) recommend the use of the risk 
stratification based on the EHS-ESC guidelines.21 In South Africa, the GRS is calculated using the 
chart from the SAHS guideline. This is known as the South African Hypertension Society Global Risk 
Score (SAHS/GRS) chart. Using the SAHS/GRS, the patient is classified in one of the two CVR 
clusters: either low/moderate added risk or high/very high added risk. The first group of patients 
assessed as having low or moderate CVR will undergo three to six months of lifestyle modification 
without drug treatment. They will be monitored regularly during this period and will at the end of each 
cycle be reclassified in one of the two clusters of CVR grading, and be treated accordingly. The 
second group labelled as high and very high added CVR leave the health care facility with a plan for 
lifestyle modification and at least one anti-hypertensive drug. The SAHS/GRS is a laboratory-based 
score. 
Some laboratory-based CVRFs used to determine the GRS have included in their equation variables 
like the LDL-Cholesterol level, which is less accessible in resource-limited settings.23 Therefore the 
WHO and the IHS advocate for the non-laboratory-based global risk assessment (NLB-GRA) to be 
used in low-income countries.5 The ”WHO-Scores” ignore the cholesterol level and are developed 
for each WHO world region.34 The “Gaziano” and the “Non-Laboratory Framingham” (NLB-
Framingham) GRS substitute cholesterol for BMI. 20,35 This makes those scores simple, accessible 
and clinically available in resource-constrained settings. Many studies have demonstrated the 
performance of those scores around the world.26,35 Because of variability in the prevalence of CVRFs, 
it is recommended that a validation study be conducted locally on a given population before adopting 
any GRS algorithm developed elsewhere.32 
1.5. Cost and other implications related to global cardiovascular risk assessment 
Establishing CVR on a patient includes a combination of clinical data and laboratory studies such as 
cholesterol level. A GRS without cholesterol is cost-saving. Patients screened as high risk can then 
be treated efficiently with a combination of modalities including determining and treating HT and an 
elevated cholesterol level. Patients stratified as low risk will benefit from lifestyle modification and 
regular follow-up. 
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2. RATIONALE AND JUSTIFICATION 
South Africa carries a high burden of CVD with HT as the most prevalent risk factor.12 The efficient 
and evidence-based approach to the treatment of HT lies in determining the global CVR of the 
individual. This helps us to set up an efficient and cost-effective treatment. Many GRS systems have 
been developed, each specific to a given population and its CVR profile.22 The current national 
guideline developed by the SAHS recommends the use of a laboratory-based cardiovascular risk 
score derived from the EHS-ESC: the SAHS/GRS.21 On the other hand, the WHO recommends the 
use of a non-laboratory-based GRS (WHO/GRS) calculated from the chart specific for the Southern 
African region: the WHO/IHS Chart AFR E.5, 34 
The current SAHS/GRS used in South Africa implies determination of global CVR after obtaining 
clinical data from patients, as well as investigations including the cholesterol level and determination 
of left ventricular hypertrophy by electrocardiography (ECG). On the other hand, the WHO/GRS 
determines the global CVR after obtaining only clinical data. 
To my knowledge, there is no study comparing the SAHS/GRS Chart and the WHO/GRS in the rural 
South African region of Mafikeng. Such a study will provide grounds for the use of NLB-GRA in rural 
primary care in South Africa where it is needed most. Availability of NLB-GRA in South African PHC 
will assist primary care workers to accurately assess the global CVR, and this will benefit their 
patients from the first visit. Comparing the current SAHS/GRS with the proposed WHO/GRS for 
Southern Africa in a rural setting will answer many questions such as the level of performance of the 
WHO/GRS score in classifying rural hypertensive patients on the correct level of CVR. The 
anticipated cost-saving linked to the non-inclusion of laboratory studies such as cholesterol level 
testing is imperative in the light of the ongoing dwindling of financial resources in the province and 
the country at large. This will also decrease the risk of patient loss to follow-up, the loss of specimens 
to/from the lab, the need for patients to wait for laboratory results (cholesterol levels) as well as the 
financial burden on patients having to come back for blood results before being risk-categorised. 
Costs will nose-dive, making quality service delivery less cumbersome for health care workers and 
patients alike. The WHO/GRS is based on clinical variables, making it easy to use in primary care. 
Because of time and resource limitations, the present study will be limited to a specific number of 
patients. 
3. RESEARCH QUESTION, AIM AND OBJECTIVES 
Research question: In a convenient sample, are the Global Risk Scores (GRSs) using the Southern 
African Hypertension Society chart (SAHS/GRS)21 and the WHO/IHS Chart AFR E34 (WHO/GRS) 
equivalent and cost-effective? 
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Aim: 
To compare the cardiovascular risk scores calculated from the SAHS/GRS and the WHO/GRS on 
hypertensive patients attending Mafikeng Provincial (MPH) and to determine the difference in 
financial cost between the two scores. 
 
Objectives: 
1. To describe the socio-demographic profile of participants 
2. To determine the proportion of cardiovascular risk factors among participants 
3. To grade hypertensive patients using the SAHS/GRS 
4. To grade hypertensive patients using the WHO/GRS 
5. To evaluate the correlation between the pairs of calculated risk scores in every participant 
6. To compare the financial costs of the SAHS/GRS and the WHO/GRS 
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METHODS 
4. STUDY DESIGN 
This will be a cross-sectional prospective preliminary study. 
5. STUDY SETTING 
Mafikeng Provincial Hospital (MPH) serves as a level 1 referral hospital for Mafikeng Sub-district 
health facilities (community health centres, primary health clinics and general practices) and as a 
level 2 hospital for different district hospitals in Ngaka Modiri Molema district. Mafikeng Provincial 
Hospital is situated in Mafikeng, the capital of North West Province. The largest part of Mafikeng 
Sub-district is rural. Mafikeng Provincial Hospital has 409 beds, combining level 1 and 2 services. 
The Family Medicine Department together with the Gateway Clinic constitutes the level one 
component of Mafikeng Provincial Hospital. The Family Medicine Department consists of 4 units: the 
accident and emergency unit, the general outpatient department, the wellness clinic and the short 
stay ward. Hypertensive patients from different primary care facilities within Mafikeng Sub-district 
are referred to Mafikeng Provincial Hospital via the General Outpatient Department where a family 
physician, a registrar and an intern review them initially. The most frequent reason for referral is 
uncontrolled HT. The General OPD collaborates with specialised “clinics” or OPDs from different 
level 2 departments like the “HT clinic” in the Medical Outpatient Department where complex clinical 
situations and patients who need long-term specialised follow-up are seen. Currently 800 
hypertensive patients are registered in the Medical OPD and an average of 1,200 hypertensive 
patients are seen annually in the General OPD. 
6. STUDY POPULATION AND SAMPLING 
All hypertensive patients referred from primary care facilities in Mafikeng Sub-district and who are 
initially seen in the Family Medicine General OPD represent the study population. The recruitment 
of patients will take place in this department. This study will determine the feasibility of a 
cardiovascular estimate using the two different scoring systems described above and will include a 
cost comparison. This preliminary study will serve as a reference for a complete investigation 
including an adequate sample. This study focuses on hypertensive patients from primary care 
facilities in Mafikeng Sub-district. 
The average number of new and follow-up hypertensive patients registered during 2014 was 1,200. 
This number was included in the Raosoft sample size calculator using a confidence level of 95%, a 
variability degree of 50% and a margin error of 5%.36 The calculator generated a minimum number 
of 292 patients as a representative sample to be studied. However, to allow parametric statistical 
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analysis, this pilot study will only include 120 patients: 60 males and 60 females. Consecutive 
patients consulting the outpatient department at Mafikeng Provincial Hospital who accept to 
participate in the study will be enrolled until the sample size is reached. Each patient participating in 
this study will serve as is own control: From each patient data serving to determine cardiovascular 
risk using both equations will be collected. 
7. INCLUSION AND EXCLUSION CRITERIA 
All hypertensive patients of 18 years and older referred from Mafikeng Sub-district primary care 
facilities between March 1st and June 30th 2016 presenting in the outpatient department will be 
included in this study, depending on their informed consent. Patients who need emergency 
treatment, those unable to stand or to comply with the anthropometric measurement standards 
described below, and patients referred from other hospitals will be excluded. Patients with a history 
of cardiovascular events such as stroke and IHD will also be excluded. 
8. DATA COLLECTION 
8.1. Data collection tool 
The WHO stepwise approach to non-communicable disease risk factor surveillance (STEPS) will be 
used for data collection. The WHO STEPS Instrument will serve as a support for data collection. A 
data collection sheet with identifiers is attached in appendix 4.  This is a standardised and validated 
data collection instrument developed by the WHO intending to generate local data comparable with 
other sites worldwide, and it is recommended for collection of CVRFs.37 
8.2. Process of data collection 
All hypertensive patients will be approached individually while in the pre-vitals room. A research 
team member will give an extensive verbal explanation of this study. Patients willing to participate in 
the study will undergo an informed consent process following the points detailed in the consent form 
(see Appendix 1). At the end of this dialogue all hypertensive patients, irrespective of whether they 
agree to participate in this study, will receive an explanation of how to collect a urine sample. A urine 
sample bottle will be given to each one and they will be invited to collect urine and return it to the 
vital signs room. Patients who agree to participate in the study will be invited to sign the consent 
form in the presence of a nurse who is not a member of the study team and who will act as a witness. 
Patients not willing to participate will be given normal care according to hospital standards and 
current national guidelines. After signing the informed consent form, a special sub-file will be included 
in the hospital record. This sub-file will contain the WHO STEPS Instrument designed to assist in 
data collection.37 A discriminating colour-coded “orange dot” will be glued to the front of the file cover 
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to avoid replication of recruitment. The patient will be invited into the vital signs room where a nurse 
trained for this study will record his/her weight, height, BP, heart rate and urine dipstick results. The 
patient will then be invited into the interview room, where a nurse trained to use the WHO STEPS 
approach Instrument will administer a questionnaire in English or Setswana. After the interview, the 
patient will undergo a clinical consultation including a repeat of the BP measurement and a physical 
examination. The patient will enter the investigation room where a blood sample will be drawn and 
an ECG will be recorded. The sub-file will be withdrawn from the patient file and kept for data 
capturing. Before being discharged, the patient will receive a brief feedback on the entire consultation 
and will be invited for a subsequent visit where definitive management will be offered according to 
the findings and the national guidelines. To conduct this process, a team of four members will be 
needed: three nurses and one doctor. Nurse one will be in the pre-vital room to invite hypertensive 
patients, nurse two in the vital room, the researcher in the consulting room and nurse three in the 
investigation room. 
8.3. variables to be collected 
At the end of this study, I will need to establish the cardiovascular risk stratification of each participant 
using both the SAHS/GRS and the WHO/GRS. The calculated risk will be compared mutually for 
concordance. This simply means that each participant will be the patient and his own control. The 
only factor changing will be the test used to determine the cardiovascular risk level. 
9. DATA ANALYSIS 
Data recorded during the clinical interaction with the patient will include the variables listed in the 
Appendix 4. In total, 11 variables will be recorded. The data will be recorded onto an Excel 
spreadsheet and then transferred to SPSS 17.0 for summary and analysis. Categorical variables 
will be summarised by their frequency and percentage; continuous variables will be summarised by 
their mean +/- standard deviation (SD). Clusters of CVR categories will be compared using a Chi-
square test to assess similarity. Tables and charts will be used to describe and present different 
data summaries. 
9.1. Establishing global cardiovascular risk using the SAHS/GRS 
Using Table 4 (Appendix 6), the number of risk factors will be plotted in the first column of the table 
and the level of the mean BP in the first row. Among the risk factors, the left ventricular 
hypertrophy will be determined using information from the ECG to populate the cornel score as 
detailed in the guideline.21 The intersection corresponds to the level of CVR. 
The SAHS/GRS discriminates four groups of CVR namely low, moderate, high and very high added 
CVR groups. According to this guideline, the first group identified as having low added CVR will be 
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followed up for six to twelve months of lifestyle modification. The second group identified as having 
moderate added CVR will be prescribed a lifestyle modification and followed up for three to six 
months. The third group identified as having high added CVR will immediately be started on one 
antihypertensive drug in addition to advice/health education on lifestyle modification.  The fourth 
group classified as having very high CVR will also be commenced on one antihypertensive drug in 
combination with lifestyle modifications. 
 
From a therapeutic perspective, all four CVR groups can be divided into two groups. The first group 
will start treatment with one lifestyle modification and the patients in this group will be reviewed during 
3, 6 and 12-month follow-up, with treatment changes depending on the level of risk. The second 
group will be combining one antihypertensive drug with lifestyle modification from the beginning. For 
this study, the first group of patients managed with lifestyle modification only will be included in the 
first category and the second group will include those managed with at least one antihypertensive 
drug. 
9.2. Establishing global cardiovascular risk using the WHO/GRS 
Using Table 3 (Appendix 5), every patient’s clinical data will be plotted to determine the percentage 
of CVR. Patients scoring less than 30% will be classified as Category 1. Those scoring equal to or 
more than 30% will be included in Category 2, since they will be managed with at least one 
antihypertensive drug from the beginning. 
 
9.3. Comparison of the two scores: WHO/GRS vs. SAHS/GRS 
All patients will be classified into one of the two categories of CVR: low and low to moderate or with 
a CVR less than 30% (Category 1), or high to very high or with a CVR equal to or more than 30% 
(Category 2). Using the current SAHS/GRS as reference score (“gold standard”), the sensitivity and 
specificity of the WHO/GRS to correctly classify patients into one of the two CVR clusters will be 
established. This result will be presented in a 2X2 table. Multivariate statistical manipulation will be 
done to improve the performance of the WHO/GRS by including different clinical variables in a 
multivariate model. Multiplying the number of patients correctly classified as low to moderate risk 
with the cost of cholesterol testing, the total cost saving will be established. The ratio of high-risk 
patients falsely classified as low risk will be determined and the number needed to harm (NNH) will 
be established. The statistical test plan is presented in Table 1 below. 
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Table 1. Statistical test plan 
Objectives Data collection (Variables 
and/or data needed) 
Planned statistical 
analysis 
1. To describe the socio-
demographic profile of 
participants 
Categorical variables like race 
and education 
Frequency and 
percentage 
Continuous variables like age Range, mean and 
standard deviation 
2. To determine the proportion 
of CVRFs among participants 
Proportion of risk factors such 
as smoking status, high 
cholesterol level and left 
ventricular hypertrophy present 
in hypertensive patients 
Percentage 
3. To grade hypertensive 
patients using the Global Risk 
Assessment from the South 
African Hypertension Society 
Chart (GRA/SAHS Chart) 
Risk factors, SAHS-GRA Chart 
to obtain two clusters of 
grading (A) low or moderate 
and (B) high and very high 
added CVR 
Frequency and 
percentage 
4. To grade hypertensive 
patients using the World 
Health Organization and 
International Hypertension 
Society Chart for the South 
African region (WHO/HIS 
Chart AFR E) 
Combine risk factors according 
to WHO/IHS and AFR E charts 
to obtain two clusters of 
grading: (C) low or moderate 
and (D) high and very high 
added CVR 
 
Frequency and 
percentage 
5. To compare the CVR score 
of hypertensive patients in 
MPH calculated from the 
GRA/SAHS Chart and the 
WHO/HIS Chart AFR E 
Comparison of percentage of 
patients classified into one of 
the two clusters or categories 
of cardiovascular grading from 
SAHS/GRS and WHO/GRS 
charts 
 
 
Sensitivity and specificity 
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6.1. To calculate the cost-
saving derived from the 
WHO/GRS 
 
6.2. To calculate the number 
needed to harm (NNH) 
 
Number of patients correctly 
classified using WHO/GRS 
 
Ratio of number of wrongly 
classified as low risk by the 
WHO/GRS and ratio of 
patients classified as low risk 
using the SAHS/GRS 
 
Cholesterol test price 
multiply by the number of 
patient correctly classified 
using WHO/GRS. 
Inverse of the absolute 
risk increase (ARI) from 
the ratio of patients 
wrongly classified as 
Category 1 or low risk 
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10. TIME FRAME AND FINANCES 
 
Table 2. Financial plan 
Item Quantity Price Total price 
Printing and stationary 120 x 15 = 900 pages, sub-
file covers & miscellaneous 
R1/copy            
R1.50/sub
file 
R1,980 
 
ECG paper and leads 
 
2 packs of paper and 1 box 
of 1000 disposable leads 
R800      R800* 
Cholesterol level test 
Data collection and capture, 
team transport and 
incentives 
120 tests 
4 team members 
R125 
R2,000 
R15,000* 
R8,000 
Proof reading 
Publication fees (CVJA) 
X2 R1,000 
    R600 
R2,000 
   R600 
Pitfalls   R1,000 
Total 
Without sponsored items 
  R29,380 
R13,580 
* Sponsored items 
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Fig.1. Gantt chart 
 
Mar  
2016 
  Nov 
2016 
Dec 
2016 
 Feb 
2017 
Mar 
2017 
Apr  
2017 
Research Proposal for 
ethics clearance 
      
Literature Review               (Pilot study)  Literature review    
    Data collection    
     Data Capturing   
      Data Analysis  
       Final report 
       Publications 
Feedback 
 
 
11. ETHICAL CONSIDERATIONS 
11.1. Confidentiality and autonomy to participate in the study 
Interviews and physical examinations will be conducted in private rooms ensuring participants’ 
privacy and dignity. Patient information will be kept confidential and treated with anonymity, as 
explained in the following sentence. A codification number will be linked to each patient’s information 
and the file linking the specific code to the corresponding patient will be stored under lock and key 
at a location with restricted access, only accessible to the researcher. Individual informed consent 
will be sought after a full explanation of the study aim, objectives and methodology. A copy of the 
signed consent form will be kept in the patient’s folder. There will be no discrimination should the 
patient refuse to be part of the study. Since this study will only benefit indirectly to the patient; they 
will be made aware of this during the informed consent process. 
Ethical clearance will be requested from the WITS Human Research Ethics Committee, as well as 
authorisation from the hospital management to conduct this study. 
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11.2. Finances and cost 
This study will not create extra costs for the Department of Health or the institution where it will 
be conducted. Patient data, particularly those related to costly investigation (Cholesterol and ECG), 
will be collected according to the guideline. In fact, according to the national guideline on HT in South 
Africa, hypertensive patients are required to have an annual ECG and cholesterol testing. When 
those results are available and not older than twelve months, no new investigation will be required. 
Those results will be used for the study since they will still be valid according to the national guideline. 
An ECG and a cholesterol level test will be sought only when they are either not available or older 
than twelve months. Authorisation to comply with the guideline and to request new investigations 
when not available has been requested from the hospital management. 
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APPENDICES 
APPENDIX 1A. Informed consent (Version 2) 
Consent Form 
 
STUDY TITLE: COST ANALYSIS AND COMPARISON OF TWO GLOBAL CARDIOVASCULAR RISK 
SCORES IN HYPERTENSIVE PATIENTS AT MAFIKENG PROVINCIAL HOSPITAL: A PRELIMINARY 
EXPLORATORY STUDY 
Dear Patient, 
You are currently consulting the Out Patient department of Mafikeng Provincial Hospital for treatment of 
problems you are currently experiencing. Mafikeng Provincial Hospital not only renders treatment but is also 
actively involved in conducting research aimed at improving the quality of care that we deliver.  
You are invited to participate in the study with the title is written above. You have been handed an information 
sheet giving details of the current study. In summary this study aims to compare 2 risk stratifications formula 
for people with hypertension in our region. The result of this study will benefit future user of health care in our 
district because stratification will be possible from the first consultation without using invasive and laboratory 
procedures. You will also benefit from this study by having your cardiovascular risk review and updated. The 
researcher will give you an individual feedback on your risk. This study includes answering questions, 
measurements and blood tests. Collection of blood test, 8 ml form the back of the hand or the forearm is linked 
to a needle prick pain. 
All data collected during this study will be handled anonymously. The recording will be made under a code 
generated as soon as you agree to participate to maintain anonymity. A specific consent is needed to remove 
decode any data. You are free to decline participation to this study or to withdraw any time during the study. 
This will not affect your care in any way whatsoever. This study has been approved by the Human Research 
Ethics Committee (Medical) of the University of the Witwatersrand, certificate number: 
……………………………………. 
Should you wish to contact us at any stage regarding consent, contact Dr MBUILU JP at 0837662832. 
(Please tic)  A. Consent Given    B. Consent Not Given 
I___________________________________ hereby give consent to participate freely in the above described 
research: 
PATIENT: _____________________________ DATE: ____________________________ 
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APPENDIX 1B. INFORMATION DOCUMENT (v2) 
Study title: Cost analysis and comparison of two global cardiovascular risk scores in hypertensive patients at 
Mafikeng Provincial Hospital: a preliminary exploratory study 
Greeting: 
Introduction: 
I, Dr Mbuilu JP, am doing research/study on Hypertension. In this study I want to learn if the stratification of 
hypertension risk can be made without using some information from the laboratory as recommended by the 
current South African guideline. We hope that results from this study will benefit future patient consulting our 
peripheral health facility for hypertension. 
Invitation to participate: I am inviting you to take part in a research study. 
What is involved in the study – If you agree to participate in this study, I will ask you few questions about your 
age, smoking and drinking habit and history related to hypertension on you and your family during a 8 minutes 
interview, record some measurement on your body (7 minutes) and collect 8 ml of blood (two big spoon) from 
your forearm or back of your hand. This blood will be tested for the level of cholesterol and renal function. This 
study need 120 participants to be completed. 
Risks: drawing of blood is accompany by a needle prick pain. 
Benefits of being in the study include an update of your cardiovascular risk and an adjustment of your 
treatment accordingly (counselling on diet and exercise and prescription). This is an indirect benefit from this 
study. 
The participant will be given pertinent information on the study while involved in the project and after the results 
are available. 
Participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the 
participant is otherwise entitled, and that the subject may discontinue participation at any time without penalty 
loss of benefits to which the participant is otherwise entitled. 
No extra cost when consenting to this study 
Confidentiality: Efforts will be made to keep personal information confidential.  Absolute confidentiality cannot 
be guaranteed.  Personal information may be disclosed if required by law. 
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Organizations that may inspect and/or copy your research records for quality assurance and data analysis 
include groups such as the Research Ethics Committee and the Medicines Control Council (where 
appropriate). 
If results are published, may lead to individual / cohort identification. 
Contact details of researcher – for further information / reporting of study related adverse events: Dr Mbuilu, 
Tel.: 0837662832 
Contact details of HREC administrator and chair – for reporting of complaints / problems: WITS 
University,Tel: +27 (0)11-717-1252 
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APPENDIX 2. WHO STEPS Instruments and GPAQ links: 
http://www.who.int/chp/steps/GPAQ_EN.pdf 
http://www.who.int/chp/steps/STEPS_Instrument_v2.1.pdf 
FOR DATA COLLECTION 
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APPENDIX 3. Authorisation from Mafikeng Provincial Hospital CEO 
   
 
 60 
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APPENDIX 4. List of variables to be collected 
1. Age (years as at the last birthday) 
2. Gender (Male or female) 
3. Level of systolic and diastolic BP (mmHg) 
4. Smoking status 
5. Dyslipidaemia defined by: 
- total cholesterol >5.1 mmol/l OR 
- LDL >3.0 mmol/l OR 
- HDL men<1 and women < 1,2 mmol/l 
6. Diabetes mellitus 
7. Family history of early onset of CVD (men <55 years; women <65 years) 
8. Waist circumference (Cm) 
9. ECG with standard calibration of 10 mv = 10mm and 25 mm/sec 
10. Cornell score: (R in aVL + S in V3 + 6 in female) X QRS duration > 2440 (mm/ms) 
11. Microalbuminuria and eGFR (serum creatinine) 
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APPENDIX 5. Table 3. WHO/GRS – 2 Charts for estimation of cardiovascular risk. 
 
Note: - Low and moderate cardiovascular risk or Category 1: equivalent to less than 30%. 
 - High and very-high cardiovascular risk or Category 2: equivalent to equal or more than 30% 
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APPENDIX 6. Table 4. SAHS/GRS - Chart 
 
Note 
 64 
- Low and moderate cardiovascular risk or Category 1: equivalent to less than 30%. 
- High and very-high cardiovascular risk or Category 2: equivalent to equal or more than 30%  
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APPENDIX 7.  DATA COLLECTION SHEET AND TABLE FOR CODE AND ANONYM 
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ANONYMOUS TABLE FOR CODES  
ID CODE NAME SURNAME FILE NUMBER OTHER 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
